164 related articles for article (PubMed ID: 24411213)
1. Challenges and recommendations for early identification of metastatic disease in prostate cancer.
Crawford ED; Stone NN; Yu EY; Koo PJ; Freedland SJ; Slovin SF; Gomella LG; Berger ER; Keane TE; Sieber P; Shore ND; Petrylak DP;
Urology; 2014 Mar; 83(3):664-9. PubMed ID: 24411213
[TBL] [Abstract][Full Text] [Related]
2. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
Morris MJ; Akhurst T; Osman I; Nunez R; Macapinlac H; Siedlecki K; Verbel D; Schwartz L; Larson SM; Scher HI
Urology; 2002 Jun; 59(6):913-8. PubMed ID: 12031380
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic challenges of clonal heterogeneity in prostate cancer.
Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
[No Abstract] [Full Text] [Related]
4. Prostate-specific antigen-negative prostate cancer recurrence?
Froehner M; Abolmaali N; Wirth MP
Urology; 2013 Feb; 81(2):e17-8. PubMed ID: 23374851
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
Danila DC; Heller G; Gignac GA; Gonzalez-Espinoza R; Anand A; Tanaka E; Lilja H; Schwartz L; Larson S; Fleisher M; Scher HI
Clin Cancer Res; 2007 Dec; 13(23):7053-8. PubMed ID: 18056182
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic imaging in bone metastasis from prostate cancer].
Arisaka Y; Nakazawa A; Endo K
Nihon Rinsho; 2011 Jun; 69 Suppl 5():285-90. PubMed ID: 22207987
[No Abstract] [Full Text] [Related]
7. [Metabolic and osteogenic pattern of prostate cancer bone metastases].
García JR; Riera E; Valls E; Soler M; Moragas M; Lomeña F
Rev Esp Med Nucl Imagen Mol; 2013 Jan; 32(1):33-6. PubMed ID: 22835661
[TBL] [Abstract][Full Text] [Related]
8. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
9. The association between measures of progression and survival in castrate-metastatic prostate cancer.
Scher HI; Warren M; Heller G
Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
[TBL] [Abstract][Full Text] [Related]
10. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay.
Tewfik JN; Greene GS
Curr Probl Diagn Radiol; 2008; 37(4):178-88. PubMed ID: 18502325
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted MR imaging: adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases?
Lecouvet FE; Vande Berg BC; Malghem J; Omoumi P; Simoni P
Radiology; 2009 Aug; 252(2):624. PubMed ID: 19703896
[No Abstract] [Full Text] [Related]
13. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Rezvani H; Haghighi S; Ghadyani M; Attarian H
Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
[TBL] [Abstract][Full Text] [Related]
14. Posttherapy imaging of musculoskeletal neoplasms.
Garner HW; Kransdorf MJ; Peterson JJ
Radiol Clin North Am; 2011 Nov; 49(6):1307-23, vii. PubMed ID: 22024300
[TBL] [Abstract][Full Text] [Related]
15. Chest-Wall Metastasis of Prostate Cancer.
Matei V; Bhushan S
J Gen Intern Med; 2015 Dec; 30(12):1888. PubMed ID: 25759188
[No Abstract] [Full Text] [Related]
16. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases.
Luboldt W; Küfer R; Blumstein N; Toussaint TL; Kluge A; Seemann MD; Luboldt HJ
Radiology; 2008 Dec; 249(3):1017-25. PubMed ID: 18849502
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in metastatic prostate cancer.
Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
[TBL] [Abstract][Full Text] [Related]
18. Technology insight: monoclonal antibody imaging of prostate cancer.
Bander NH
Nat Clin Pract Urol; 2006 Apr; 3(4):216-25. PubMed ID: 16607370
[TBL] [Abstract][Full Text] [Related]
19. Baseline staging of newly diagnosed prostate cancer: a summary of the literature.
Prando A
Int Braz J Urol; 2004; 30(4):341-2. PubMed ID: 15679977
[No Abstract] [Full Text] [Related]
20. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
